Answers are grounded in this paper and cite their sources.
Leucine is the only physiologic amino acid that canstimulate insulin release by itself, and a great dealof evidence suggests that leucine does this by al-losterically activating glutamate dehydrogenase (GDH). GDH catalyzes the oxidative deamination of endog-enous glutamate, which is present at a high concentration in the pancreatic b-cell. Studies that support this role of leu-cine include the fact that leucine and 2-aminobicyclo[2.2.1] heptane-2-carboxylic acid (BCH), a nonmetabolizable leucine analog, are activators of GDH and promote insulin release from pancreatic islets (1–4). Although the addition to pan-creatic islets of glutamine alone—which by its conversion to glutamate enormously increases the intracellular concentra-tion of glutamate—does not stimulate insulin release, adding glutamine in the presence of leucine or BCH causes a robust stimulation of insulin release. Patients with mutations in the region of the GDH gene that encodes the part of the GDH protein where the allosteric inhibitor guanosine triphosphate (GTP) binds to the enzyme suffer from hyperinsulinism and hypoglycemia (5), and this indicates that GDH is in-volved in insulin secretion in humans. In addition, recent studies showed that short-chain 3-hydroxyacyl-CoA de-hydrogenase (SCHAD) deficiency causes hyperinsulinism secondary to a loss of inhibition of GDH by SCHAD (6). Antischizophrenic drugs can produce hyperglycemia in patients (7,8) perhaps due to their ability to inhibit GDH. Both insulin release and GDH activity are decreased by SIRT4 (9), a mitochondrial ADP-ribosyl transferase, and de-letion of GDH in b-cells partially abolishes the insulin se-cretory response (10).
No takes yet. Share an insight, caveat, or question.
Fahien et al. (2011) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: